ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Using Human Chorionic Gonadotropin (HCG) alone for the treatment of men with low testosterone.
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 156461" data-attributes="member: 13851"><p><span style="color: rgb(184, 49, 47)"><strong><em>"They were prescribed an average of 2000 IU hCG weekly, </em></strong></span><em>which is based on the bi/tri-weekly regimen of 1500 IU hCG generally prescribed to men with hypogonadotropic hypogonadism (HH) and infertility, educated on administering it subcutaneously and followed up consistently with proper documentation of follow-up testosterone (T) levels (1). Patients were asked to schedule follow-up clinic visits every 3 months, with labs taken at these times"</em></p><p></p><p></p><p></p><p></p><p><strong>RESULTS </strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)"><em>The study included 20 men. The average age was 50.3 (SD 15.6) years and ranged from 26 to 77.</em></span></strong><em><span style="color: rgb(44, 130, 201)"> <strong>On past medical history, 2 of the patients had a history of anabolic steroid use, and two had a history of prostate cancer, one of whom was post- -radical prostatectomy.</strong></span> </em><strong><em><span style="color: rgb(26, 188, 156)">These patients had an average testicular volume of 14.2cc (SD 4.3), and 3 presented with varicoceles, 2 of which were grade II and 1 of which was grade I (Table-1). </span>Indications for treatment were largely attributed to persistent complaints of one or multiple of either low libido, low energy, or erectile dysfunction, but also included infertility and insomnia. </em><span style="color: rgb(147, 101, 184)"><em>Patients received an average dose of 2000 IU weekly. </em></span></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong><em>These men presented with an average initial T of 361.8 ng/dL (SD 158.2) and improved to an average follow-up T of 519.8 ng/dL (SD 265.6). The duration of therapy for these men averaged 6 months, <span style="color: rgb(184, 49, 47)">with an average weekly hCG dose of 2000 IU.</span> </em></strong><em><span style="color: rgb(44, 130, 201)"><strong>Over this period, they experienced an average change in T of 60%. </strong></span>One-tail Mann Whitney U test demonstrated this improvement was significant, as the sample of T at baseline was significantly less (p<0.005) than that of follow-up T. This corresponded with 50% of men subjectively reporting symptom improvement. Of the 10 men who reported symptom improvement, only 2 had negative changes in testosterone levels, both by less than 15%.</em></p><p></p><p></p><p><strong>CONCLUSION </strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)"><em>Our study indicated that hCG monotherapy is a safe and efficacious treatment option for patients with symptoms of hypogonadism who do not desire fertility or may not have initial testosterone levels greater than 300 ng/dL, significantly improving testosterone levels with no associated reports of complications or side effects.</em></span></strong> <span style="color: rgb(44, 130, 201)"><strong><em>The role of hCG monotherapy in treating these men is promising. Future studies should evaluate changes in hematocrit levels in these patients, as well as the effect that baseline luteinizing hormone may play on response to hCG monotherapy. </em></strong></span></p></blockquote><p></p>
[QUOTE="madman, post: 156461, member: 13851"] [COLOR=rgb(184, 49, 47)][B][I]"They were prescribed an average of 2000 IU hCG weekly, [/I][/B][/COLOR][I]which is based on the bi/tri-weekly regimen of 1500 IU hCG generally prescribed to men with hypogonadotropic hypogonadism (HH) and infertility, educated on administering it subcutaneously and followed up consistently with proper documentation of follow-up testosterone (T) levels (1). Patients were asked to schedule follow-up clinic visits every 3 months, with labs taken at these times"[/I] [B]RESULTS [COLOR=rgb(184, 49, 47)][I]The study included 20 men. The average age was 50.3 (SD 15.6) years and ranged from 26 to 77.[/I][/COLOR][/B][I][COLOR=rgb(44, 130, 201)] [B]On past medical history, 2 of the patients had a history of anabolic steroid use, and two had a history of prostate cancer, one of whom was post- -radical prostatectomy.[/B][/COLOR] [/I][B][I][COLOR=rgb(26, 188, 156)]These patients had an average testicular volume of 14.2cc (SD 4.3), and 3 presented with varicoceles, 2 of which were grade II and 1 of which was grade I (Table-1). [/COLOR]Indications for treatment were largely attributed to persistent complaints of one or multiple of either low libido, low energy, or erectile dysfunction, but also included infertility and insomnia. [/I][COLOR=rgb(147, 101, 184)][I]Patients received an average dose of 2000 IU weekly. [/I][/COLOR] [I]These men presented with an average initial T of 361.8 ng/dL (SD 158.2) and improved to an average follow-up T of 519.8 ng/dL (SD 265.6). The duration of therapy for these men averaged 6 months, [COLOR=rgb(184, 49, 47)]with an average weekly hCG dose of 2000 IU.[/COLOR] [/I][/B][I][COLOR=rgb(44, 130, 201)][B]Over this period, they experienced an average change in T of 60%. [/B][/COLOR]One-tail Mann Whitney U test demonstrated this improvement was significant, as the sample of T at baseline was significantly less (p<0.005) than that of follow-up T. This corresponded with 50% of men subjectively reporting symptom improvement. Of the 10 men who reported symptom improvement, only 2 had negative changes in testosterone levels, both by less than 15%.[/I] [B]CONCLUSION [COLOR=rgb(184, 49, 47)][I]Our study indicated that hCG monotherapy is a safe and efficacious treatment option for patients with symptoms of hypogonadism who do not desire fertility or may not have initial testosterone levels greater than 300 ng/dL, significantly improving testosterone levels with no associated reports of complications or side effects.[/I][/COLOR][/B][I] [/I][COLOR=rgb(44, 130, 201)][B][I]The role of hCG monotherapy in treating these men is promising. Future studies should evaluate changes in hematocrit levels in these patients, as well as the effect that baseline luteinizing hormone may play on response to hCG monotherapy. [/I][/B][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Using Human Chorionic Gonadotropin (HCG) alone for the treatment of men with low testosterone.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top